DUBLIN, Nov. 23, 2023 /PRNewswire/ — The “Prosthetic joint infections – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Prosthetic joint infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
“Prosthetic joint infections- Pipeline Insight, 2023” report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Prosthetic joint infections pipeline landscape is provided which includes the disease overview and Prosthetic joint infections treatment guidelines.
The assessment part of the report embraces, in depth Prosthetic joint infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Prosthetic joint infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Prosthetic joint infections R&D. The therapies under development are focused on novel approaches to treat/improve Prosthetic joint infections.
Prosthetic joint infections Emerging Drugs Chapters
This segment of the Prosthetic joint infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Prosthetic joint infections Emerging Drugs
TNP 2092: TenNor Therapeutics
TNP-2092 is a multi-targeting drug conjugate that exerts antibacterial activity by inhibiting three essential targets in bacterial biofilms: RNA polymerase, DNA gyrase and topoisomerase IV. TNP-2092 has demonstrated strong bactericidal activity, a low frequency for the development of resistance, and an excellent safety profile.
The drug is in Phase II clinical developmental studies for the treatment of bacterial infections and skin and soft tissue infections. In January 2020, TenNor Therapeutics received FDA Orphan Drug Designation for TNP-2092 to treat prosthetic joint infections.
PLG0206: Peptilogics
PLG0206 is an intravenous antibiotic derived from the cationic antibiotic peptide (eCAP) platform. PLG0206 works by targeting and disrupting bacterial membranes leading to the death of bacterial cells.
PLG0206 has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for the treatment of prosthetic joint infections (PJI). Currently, the drug is in the Phase I stage of its development for the treatment of PJI.
Prosthetic joint infections: Therapeutic Assessment
This segment of the report provides insights about the different Prosthetic joint infections drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Prosthetic joint infections
There are approx. 5+ key companies which are developing the therapies for Prosthetic joint infections. The companies which have their Prosthetic joint infections drug candidates in the most advanced stage, i.e. phase II include, TenNor Therapeutics.
Prosthetic joint infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Prosthetic joint infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prosthetic joint infections drugs.
Key Questions Answered
How many companies are developing Prosthetic joint infections drugs?
How many Prosthetic joint infections drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Prosthetic joint infections?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Prosthetic joint infections therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Prosthetic joint infections and their status?
What are the key designations that have been granted to the emerging drugs?
Key Players
Adaptive Phage Therapeutics
TenNor Therapeutics
Peptilogics
Key Products
Bacteriophage
TNP 2092
PLG0206
Phases
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Molecule Type
Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Product Type
Prosthetic joint infections Report Insights
Prosthetic joint infections Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Prosthetic joint infections Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/2vdevw
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
